Ameriprise’s Genomic Health, Inc. GHDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
Sell
-254,839
Closed -$17.3M 3822
2019
Q3
$17.3M Buy
254,839
+14,731
+6% +$1.01M 0.01% 1248
2019
Q2
$14M Buy
240,108
+92,429
+63% +$5.48M 0.01% 1458
2019
Q1
$10.3M Buy
147,679
+42,621
+41% +$3.16M ﹤0.01% 1677
2018
Q4
$6.77M Sell
105,058
-93,658
-47% -$6.57M ﹤0.01% 1909
2018
Q3
$14M Sell
198,716
-330,388
-62% -$19.3M ﹤0.01% 1600
2018
Q2
$26.7M Sell
529,104
-982,863
-65% -$39M 0.01% 992
2018
Q1
$47.3M Buy
1,511,967
+1,414,051
+1,444% +$46.9M 0.02% 688
2017
Q4
$3.35M Buy
97,916
+11,192
+13% +$357K ﹤0.01% 2385
2017
Q3
$2.78M Buy
86,724
+5,721
+7% +$180K ﹤0.01% 2439
2017
Q2
$2.64M Buy
81,003
+30,089
+59% +$953K ﹤0.01% 2469
2017
Q1
$1.6M Sell
50,914
-1,978
-4% -$58.5K ﹤0.01% 2682
2016
Q4
$1.55M Buy
52,892
+34,466
+187% +$1.05M ﹤0.01% 2751
2016
Q3
$533K Buy
+18,426
New +$513K ﹤0.01% 3172
2014
Q4
Sell
-110
Closed -$3K 4718
2014
Q3
$3K Buy
110
+60
+120% +$1.67K ﹤0.01% 5320
2014
Q2
$1K Hold
50
﹤0.01% 5423
2014
Q1
$1K Sell
50
-82
-62% -$2.35K ﹤0.01% 5217
2013
Q4
$4K Sell
132
-961
-88% -$30.5K ﹤0.01% 4704
2013
Q3
$34K Sell
1,093
-80
-7% -$2.67K ﹤0.01% 4043
2013
Q2
$37K Buy
+1,173
New +$38.5K ﹤0.01% 3887

Ameriprise's GHDX Position: Q4 2019 in Review

Ameriprise sold out of Genomic Health, Inc. (GHDX) in Q4 2019, closing a stake of 254,839 shares — an estimated $17.3M sold.

Ameriprise first reported a position in GHDX in Q2 2013 and held it in 19 quarters. The position peaked at $47.3M in Q1 2018. 0 funds tracked by Wall St. Rank hold GHDX as of Q4 2019.

  • Ameriprise reported no remaining Genomic Health, Inc. position as of Q4 2019 after selling out during the quarter.
  • Ameriprise sold 254,839 Genomic Health, Inc. shares in Q4 2019, an estimated $17.3M.
  • Ameriprise first reported a position in Genomic Health, Inc. in Q2 2013 and held it in 19 quarters.
  • Ameriprise's Genomic Health, Inc. position peaked at $47.3M in Q1 2018.
  • 0 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q4 2019.

Based on Ameriprise's 13F filing for Q4 2019, filed 14 Feb 2020.